Is LFCR or KPTI more profitable?

Lifecore Biomedical has a net margin of -29.93% compared to Karyopharm Therapeutics' net margin of -153.28%. Company Net Margins Return on Equity Return on Assets Lifecore Biomedical -29.93% N/A -16.16% Karyopharm Therapeutics -153.28% N/A -145.18%

Do analysts prefer MENS or KPTI?

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 514.97%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Jyong Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jyong Biotech 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Karyopharm Therapeutics 1 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.57

Which has higher valuation and earnings, MENS or KPTI?

Jyong Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Jyong Biotech N/A N/A -$4.67M N/A N/A Karyopharm Therapeutics $146.07M 0.29 -$196.04M -$13.09 N/A

Is MENS or KPTI more profitable?

Jyong Biotech has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Company Net Margins Return on Equity Return on Assets Jyong Biotech N/A N/A N/A Karyopharm Therapeutics -153.28% N/A -145.18%

Is NRXP or KPTI more profitable?

Karyopharm Therapeutics has a net margin of -153.28% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Karyopharm Therapeutics -153.28% N/A -145.18%

Does the media favor NRXP or KPTI?

In the previous week, NRx Pharmaceuticals had 14 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 18 mentions for NRx Pharmaceuticals and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.47 beat NRx Pharmaceuticals' score of -0.30 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment NRx Pharmaceuticals 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to AARD or KPTI?

In the previous week, Aardvark Therapeutics had 27 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 31 mentions for Aardvark Therapeutics and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.47 beat Aardvark Therapeutics' score of 0.04 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Aardvark Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 25 Neutral mention(s) 0 Negative mention(s) 2 Very Negative mention(s) Neutral Karyopharm Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Karyopharm Therapeutics (KPTI) Competitors

$1.87 -0.07 (-3.61%)

As of 08/28/2026 04:00 PM Eastern

Compare

KPTI vs. LFCR, MENS, UNCY, NRXP, and AARD

Should you buy Karyopharm Therapeutics stock or one of its competitors? Karyopharm Therapeutics's main competitors and comparable companies include Lifecore Biomedical (LFCR), Jyong Biotech (MENS), Unicycive Therapeutics (UNCY), NRx Pharmaceuticals (NRXP), and Aardvark Therapeutics (AARD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Lifecore Biomedical (NASDAQ:LFCR) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Lifecore Biomedical presently has a consensus price target of $6.50, suggesting a potential upside of 43.17%. Karyopharm Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 514.97%. Given Karyopharm Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Lifecore Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifecore Biomedical	1 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Karyopharm Therapeutics had 3 more articles in the media than Lifecore Biomedical. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 1 mentions for Lifecore Biomedical. Lifecore Biomedical's average media sentiment score of 1.89 beat Karyopharm Therapeutics' score of 0.47 indicating that Lifecore Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Lifecore Biomedical	Very Positive
Karyopharm Therapeutics	Neutral

Lifecore Biomedical has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, indicating that its share price is 10% less volatile than the broader market.

Lifecore Biomedical has higher earnings, but lower revenue than Karyopharm Therapeutics. Lifecore Biomedical is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifecore Biomedical	$128.87M	1.33	-$40.50M	-$1.07	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

Lifecore Biomedical has a net margin of -29.93% compared to Karyopharm Therapeutics' net margin of -153.28%.

Company	Net Margins	Return on Equity	Return on Assets
Lifecore Biomedical	-29.93%	N/A	-16.16%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

83.4% of Lifecore Biomedical shares are owned by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 32.7% of Lifecore Biomedical shares are owned by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lifecore Biomedical beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Jyong Biotech?

Jyong Biotech (NASDAQ:MENS) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, media sentiment, risk, dividends and earnings.

Jyong Biotech has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%.

Company	Net Margins	Return on Equity	Return on Assets
Jyong Biotech	N/A	N/A	N/A
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

66.4% of Karyopharm Therapeutics shares are held by institutional investors. 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 514.97%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Karyopharm Therapeutics is more favorable than Jyong Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jyong Biotech	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

In the previous week, Karyopharm Therapeutics had 3 more articles in the media than Jyong Biotech. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 1 mentions for Jyong Biotech. Jyong Biotech's average media sentiment score of 1.89 beat Karyopharm Therapeutics' score of 0.47 indicating that Jyong Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Jyong Biotech	Very Positive
Karyopharm Therapeutics	Neutral

Jyong Biotech has higher earnings, but lower revenue than Karyopharm Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jyong Biotech	N/A	N/A	-$4.67M	N/A	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

Jyong Biotech has a beta of 2.29, meaning that its share price is 129% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Summary

Karyopharm Therapeutics beats Jyong Biotech on 8 of the 13 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, indicating that its stock price is 10% less volatile than the broader market.

In the previous week, Karyopharm Therapeutics had 3 more articles in the media than Unicycive Therapeutics. MarketBeat recorded 4 mentions for Karyopharm Therapeutics and 1 mentions for Unicycive Therapeutics. Unicycive Therapeutics' average media sentiment score of 1.87 beat Karyopharm Therapeutics' score of 0.47 indicating that Unicycive Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Unicycive Therapeutics	Very Positive
Karyopharm Therapeutics	Neutral

Unicycive Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 256.46%. Karyopharm Therapeutics has a consensus price target of $11.50, suggesting a potential upside of 514.97%. Given Karyopharm Therapeutics' higher possible upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Unicycive Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Unicycive Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Unicycive Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	215.43	-$26.56M	-$1.75	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

40.4% of Unicycive Therapeutics shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 6.0% of Unicycive Therapeutics shares are held by company insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Unicycive Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Summary

Unicycive Therapeutics beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, media sentiment, dividends, institutional ownership and profitability.

Karyopharm Therapeutics has a net margin of -153.28% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

NRx Pharmaceuticals has a beta of 2.18, suggesting that its share price is 118% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

In the previous week, NRx Pharmaceuticals had 14 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 18 mentions for NRx Pharmaceuticals and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.47 beat NRx Pharmaceuticals' score of -0.30 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
NRx Pharmaceuticals	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 66.4% of Karyopharm Therapeutics shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

NRx Pharmaceuticals has higher earnings, but lower revenue than Karyopharm Therapeutics. NRx Pharmaceuticals is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	124.97	-$28.62M	-$0.55	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

NRx Pharmaceuticals currently has a consensus target price of $34.50, indicating a potential upside of 871.83%. Karyopharm Therapeutics has a consensus target price of $11.50, indicating a potential upside of 514.97%. Given NRx Pharmaceuticals' higher probable upside, equities research analysts plainly believe NRx Pharmaceuticals is more favorable than Karyopharm Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

Summary

NRx Pharmaceuticals beats Karyopharm Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Karyopharm Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Karyopharm Therapeutics (NASDAQ:KPTI) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.

Aardvark Therapeutics has a net margin of 0.00% compared to Karyopharm Therapeutics' net margin of -153.28%. Karyopharm Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Karyopharm Therapeutics	-153.28%	N/A	-145.18%

Aardvark Therapeutics presently has a consensus target price of $15.33, suggesting a potential upside of 164.82%. Karyopharm Therapeutics has a consensus target price of $11.50, suggesting a potential upside of 514.97%. Given Karyopharm Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Karyopharm Therapeutics is more favorable than Aardvark Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Karyopharm Therapeutics	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57

66.4% of Karyopharm Therapeutics shares are owned by institutional investors. 17.8% of Aardvark Therapeutics shares are owned by insiders. Comparatively, 1.7% of Karyopharm Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aardvark Therapeutics has higher earnings, but lower revenue than Karyopharm Therapeutics. Aardvark Therapeutics is trading at a lower price-to-earnings ratio than Karyopharm Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Karyopharm Therapeutics	$146.07M	0.29	-$196.04M	-$13.09	N/A

In the previous week, Aardvark Therapeutics had 27 more articles in the media than Karyopharm Therapeutics. MarketBeat recorded 31 mentions for Aardvark Therapeutics and 4 mentions for Karyopharm Therapeutics. Karyopharm Therapeutics' average media sentiment score of 0.47 beat Aardvark Therapeutics' score of 0.04 indicating that Karyopharm Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Aardvark Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	25 Neutral mention(s)	0 Negative mention(s)	2 Very Negative mention(s)	Neutral
Karyopharm Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Aardvark Therapeutics has a beta of 3.81, suggesting that its stock price is 281% more volatile than the broader market. Comparatively, Karyopharm Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Summary

Aardvark Therapeutics beats Karyopharm Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Karyopharm Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding KPTI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

KPTI vs. The Competition

Export

Metric	Karyopharm Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$42.41M	$12.17B	$7.21B	$12.90B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	-0.14	787.65	273.16	25.42
Price / Sales	0.29	755.84	630.81	94.42
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	-0.12	10.49	11.08	6.36
Net Income	-$196.04M	$2.83B	$3.48B	$349.79M
7 Day Performance	-4.59%	0.39%	0.13%	-0.80%
1 Month Performance	-73.32%	5.34%	7.08%	4.13%
1 Year Performance	-73.70%	6.05%	24.67%	15.17%

Karyopharm Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
KPTI Karyopharm Therapeutics	2.4957 of 5 stars	$1.87 -3.6%	$11.50 +515.0%	-73.7%	$42.41M	$146.07M	N/A	380	Analyst Downgrade Gap Up
LFCR Lifecore Biomedical	2.4564 of 5 stars	$4.55 +0.2%	$6.50 +42.9%	-40.3%	$171.85M	$128.87M	N/A	690	Positive News Analyst Downgrade
MENS Jyong Biotech	N/A	$2.22 +1.8%	N/A	-95.7%	$165.74M	N/A	N/A	31	Positive News
UNCY Unicycive Therapeutics	3.2118 of 5 stars	$5.34 -5.2%	$18.75 +251.1%	+25.5%	$156.82M	N/A	N/A	9
NRXP NRx Pharmaceuticals	1.8856 of 5 stars	$3.45 -3.1%	$34.50 +900.0%	+53.0%	$154.13M	$1.23M	N/A	2	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:KPTI) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. LFCR, MENS, UNCY, NRXP, and AARD

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Summary

How does Karyopharm Therapeutics compare to Jyong Biotech?

Summary

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Summary

How does Karyopharm Therapeutics compare to NRx Pharmaceuticals?

Summary

How does Karyopharm Therapeutics compare to Aardvark Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Karyopharm Therapeutics (KPTI) Competitors

KPTI vs. LFCR, MENS, UNCY, NRXP, and AARD

How does Karyopharm Therapeutics compare to Lifecore Biomedical?

Do analysts prefer LFCR or KPTI?

Does the media refer more to LFCR or KPTI?

Which has more risk & volatility, LFCR or KPTI?

Which has higher valuation & earnings, LFCR or KPTI?

Is LFCR or KPTI more profitable?

Do institutionals and insiders have more ownership in LFCR or KPTI?

Summary

How does Karyopharm Therapeutics compare to Jyong Biotech?

Is MENS or KPTI more profitable?

Do institutionals and insiders believe in MENS or KPTI?

Do analysts prefer MENS or KPTI?

Does the media refer more to MENS or KPTI?

Which has higher valuation and earnings, MENS or KPTI?

Which has more volatility & risk, MENS or KPTI?

Summary

How does Karyopharm Therapeutics compare to Unicycive Therapeutics?

Which has more risk and volatility, UNCY or KPTI?

Does the media refer more to UNCY or KPTI?

Do analysts recommend UNCY or KPTI?

Which has preferable earnings and valuation, UNCY or KPTI?

Do institutionals and insiders believe in UNCY or KPTI?

Is UNCY or KPTI more profitable?

Summary

How does Karyopharm Therapeutics compare to NRx Pharmaceuticals?

Is NRXP or KPTI more profitable?

Which has more risk and volatility, NRXP or KPTI?

Does the media favor NRXP or KPTI?

Do insiders & institutionals have more ownership in NRXP or KPTI?

Which has preferable valuation & earnings, NRXP or KPTI?

Do analysts recommend NRXP or KPTI?

Summary

How does Karyopharm Therapeutics compare to Aardvark Therapeutics?

Is AARD or KPTI more profitable?

Do analysts recommend AARD or KPTI?

Do insiders and institutionals hold more shares of AARD or KPTI?

Which has better earnings & valuation, AARD or KPTI?

Does the media refer more to AARD or KPTI?

Which has more risk & volatility, AARD or KPTI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI vs. The Competition

Karyopharm Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools